Schools of Population Health and Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Subst Abuse Treat Prev Policy. 2020 Feb 17;15(1):14. doi: 10.1186/s13011-020-0256-8.
While there has been extensive attention to the 'demand side' - or use and adverse consequences, including mortality - of the 'opioid crisis' presently unfolding across North America, few considerations have focused on the supply side. This paper examines the supply side dynamics of this unprecedented public health phenomenon. We provide evidence for several interrelated supply-side elements that have contributed to the present public health crisis. We observe that initially, persistently high levels of prescription opioid availability and use exposed large proportions of the North American population to opioids, resulting in correspondingly high levels of medical and non-medical use (e.g., involving diversion). While various intervention measures to control prescription opioid availability and use have been implemented in recent years, leading to eventual reductions in opioid dispensing levels, these occurred late in the crisis's evolution. Moreover, these supply reductions have not been met by corresponding reductions in opioid use or demand levels. These growing discrepancies between opioid demand and prescription-based sources have left major gaps in opioid supplies. In response to such supply gaps, highly potent and toxic illicit opioid products have rapidly proliferated across North America, and become a core driver of the dramatic spikes in opioid overdose fatality levels in recent years. These supply-related interrelations are corroborated by a corresponding increase in illicit opioid-related fatalities, which arose just as medical opioid supplies began to decrease in many jurisdictions. Improved analyses and understanding of the supply-side dynamics of the opioid crisis are urgently needed in order to inform future intervention and policy development. Meanwhile, the high mortality toll related to illicit, highly toxic opioid exposure requires sustained solutions, including supply-oriented measures (e.g., safer opioid distribution for at-risk users) towards improved public health protection.
尽管人们对目前在北美发生的“阿片类药物危机”的“需求侧”(即使用和不良后果,包括死亡率)进行了广泛关注,但很少有人关注供应侧。本文考察了这一前所未有的公共卫生现象的供应侧动态。我们提供了几个相互关联的供应侧因素的证据,这些因素促成了目前的公共卫生危机。我们观察到,最初,持续高水平的处方类阿片类药物的可及性和使用使大量北美人口接触到阿片类药物,导致相应高水平的医疗和非医疗用途(例如,涉及滥用)。尽管近年来已经实施了各种控制处方类阿片类药物可及性和使用的干预措施,导致阿片类药物配给水平最终降低,但这些措施是在危机演变的后期实施的。此外,这些供应减少并没有伴随着阿片类药物使用或需求水平的相应减少。阿片类药物需求与基于处方的供应之间的差距越来越大,导致阿片类药物供应出现重大缺口。为了应对这些供应缺口,高浓度、高毒性的非法阿片类药物产品在北美迅速扩散,并成为近年来阿片类药物过量致死率急剧上升的核心驱动因素。这些与供应相关的相互关系得到了非法阿片类药物相关死亡人数相应增加的佐证,这些死亡人数出现在许多司法管辖区的医疗类阿片类药物供应开始减少的时候。迫切需要对阿片类药物危机的供应侧动态进行更好的分析和理解,以为未来的干预和政策制定提供信息。与此同时,非法、高毒性阿片类药物暴露相关的高死亡率需要持续的解决方案,包括供应导向的措施(例如,为高风险使用者提供更安全的阿片类药物分配),以改善公共卫生保护。